Cassava Technologies has announced yet another partnership in its goal of driving Africa’s artificial intelligence (AI) future. This time, they signed a Memorandum of Understanding (MoU) with ...

Cassava, also known as yuca or manioc, was once known mostly in Caribbean, African, and South American cuisines — but has grown in popularity, popping up as an ingredient in countless gluten ...

It's called cassava and it's a starchy root like vegetable. And it's become rather popular as an ingredient in gluten-free and paleo-friendly foods, like chips, breads, and cookies. But testing ...

[Cakes, pizzas, tamales, sweets using cassava.] Cakes, pizzas, tamales, sweets using cassava. Young Liset Perdomo Mateo briefly commented on a type of bread roll with a very peculiar name: "Mushinos ...

Cassava is stopping all development of simufilam in Alzheimer’s disease. Image credit: Shutterstock / Mikadun. Cassava Sciences has officially stopped the development of its investigational drug ...

Cassava Technologies has announced plans to build Africa’s first “AI Factory” — a high-performance, AI-enabled data center powered by NVIDIA’s advanced computing technology. At the ...

The licensing deal follows years of controversy for Cassava, as well as the high-profile late-stage failure of its Alzheimer’s disease drug simufilam. Embattled Cassava Sciences on Thursday entered ...

Cassava Sciences is laying off 10 employees—a third of its workforce—as the biotech seeks to conserve cash in the wake of the phase 3 fail of its lead Alzheimer’s disease drug. The RETHINK ...

Cassava says failed trial results have impacted its second Phase 3 trial, ReFocus-ALZ; decides to discontinue ReFocus-ALZ Cassava says it will continue to review the data and evaluate the next ...

AUSTIN, Texas, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a clinical-stage biotechnology company ...

Nov 25 (Reuters) - Cassava Sciences (SAVA.O), opens new tab said it will stop all trials of its Alzheimer's disease drug after it failed a late-stage study, sending shares of the drug developer ...

Cassava Sciences stock has crashed after its Alzheimer’s disease candidate simufilam failed to meet any endpoints in a Phase III study. Image credit: Gannvector / Shutterstock Cassava Sciences’ stock ...